Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
April 16 2019 - 7:00AM
Business Wire
Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today
that the companies have entered into a strategic collaboration to
discover and develop therapies for patients with nonalcoholic
steatohepatitis (NASH).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190416005296/en/
Under the terms of the three-year collaboration, insitro’s
proprietary platform will be utilized to create disease models for
NASH and discover targets that have an influence on clinical
progression and regression of the disease. The insitro Human (ISH)
platform applies machine learning, human genetics and functional
genomics to generate and optimize unique in vitro models and drive
therapeutic discovery and development. The ISH platform will
provide insights into disease progression, suggest candidate
targets, and predict patient responses to potential therapeutic
interventions. Gilead can advance up to five targets identified
through this collaboration and will be responsible for chemistry
and development against these targets.
“Gilead is committed to researching and developing treatments
for patients living with NASH, particularly those with advanced
fibrosis who have the greatest unmet need,” said John McHutchison,
AO, MD, Chief Scientific Officer and Head of Research and
Development, Gilead Sciences. “We are excited about the opportunity
to partner with insitro to tackle the scientific challenges
associated with this complex disease. Through this collaboration we
will utilize deep learning to explore the scientific underpinnings
of the biology and clinical spectrum of NASH, with the goal of
accelerating the development of highly effective treatment options
for patients with this disease.”
“NASH is a progressive liver disease that can lead to fibrosis,
cirrhosis, and liver cancer and will soon be the predominant cause
of liver transplantation in the U.S.,” said Daphne Koller, Ph.D.,
CEO and founder of insitro. “We are excited to work with Gilead, a
leader in liver disease, in bringing to bear novel tools toward
identifying new therapeutics for NASH and helping the many patients
in need around the world.”
Under the terms of the agreement, insitro will receive an
upfront payment of $15 million, with additional near-term payments
up to $35 million based on operational milestones. insitro will be
eligible to receive up to $200 million for the achievement of
preclinical, development, regulatory and commercial milestones for
each of the five Gilead targets; and up to low double-digit tiered
royalties on net sales. For programs where insitro opts in, it will
have the right to co-develop and co-detail in the U.S., receive a
profit share in China and receive milestone payments and royalties
on other ex-U.S. sales.
About NASH
Nonalcoholic steatohepatitis (NASH) is a chronic form of liver
disease characterized by excess fat in the liver, inflammation, and
liver cell damage. Inflammation and liver cell damage can cause
scarring of the liver, or fibrosis, and ultimately lead to
cirrhosis or liver cancer. NASH is more common in people with
certain conditions, including obesity and type 2 diabetes. There
are currently limited approved treatments for patients living with
NASH.
About insitro
insitro is a data-driven drug discovery and development company
that uses machine learning to transform the way that drugs are
discovered and delivered to patients. By generating
high-throughput, functional genomic data sets that align with
patient data, and interpreting those data via novel machine
learning methods, insitro builds predictive models that can
accelerate target selection and the design of effective
therapeutics. The company is building a high-throughput bio-data
factory based on state-of-the-art technologies from bioengineering,
allowing the creation of large data sets that enable cutting edge
machine learning methods to be brought to bear on key bottlenecks
in drug development. insitro was launched in 2018 with a Series A
of over $100M funded by a16z, Arch Venture Partners, Foresite
Capital, GV (formerly Google Ventures), and Third Rock Ventures, as
well as additional investments from Alexandria Venture Investments,
Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures,
Verily and other undisclosed investors. The company is located in
South San Francisco, CA. For more information on insitro, please
visit the company’s website at www.insitro.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops, and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that the parties may not realize the potential
benefits of this collaboration and Gilead may fail to develop
and/or commercialize any product candidates from this
collaboration. All statements other than statements of historical
fact are statements that could be deemed forward-looking
statements. These risks, uncertainties and other factors could
cause actual results to differ materially from those referred to in
the forward-looking statements. The reader is cautioned not to rely
on these forward-looking statements. These and other risks are
described in detail in Gilead’s Annual Report on Form 10-K for the
year ended December 31, 2018, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190416005296/en/
Gilead ContactsInvestors:Sung Lee+1
650-524-7792Media:Arran Attridge+1 650-425-8975
insitro
ContactsInvestors:ir@insitro.comMedia:Dan
Budwick, 1ABdan@1abmedia.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2023 to Sep 2024